Therapeutic advances in infectious disease · 2024
Annexin A2 antibodies in post-treatment Lyme disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miller John B, Rebman Alison W, de Flores Marcia Daniela Villegas, Wang Hong, Darrah Erika, Aucott John N
Аннотация
BACKGROUND: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).
OBJECTIVES: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.
DESIGN AND METHODS: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.
RESULTS: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.
CONCLUSION: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.
OBJECTIVES: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.
DESIGN AND METHODS: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.
RESULTS: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.
CONCLUSION: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.